Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9371176 | 0.86 | GABRP (0.45) | — | |
| SCHEMBL10198754 | 0.81 | BRD4 (0.41) | BRD4TP53CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19262034 | 0.81 | BRD4 (0.41) | BRD4TP53CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8305485 | 0.71 | ALDH1A1 (0.39) | BRD4SMN1; SMN2 | |
| SCHEMBL3601322 | 0.70 | BRD4 (0.37) | BRD4 | |
| SCHEMBL6421988 | 0.70 | BRD4 (0.44) | BRD4TP53CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL34472943 | 0.69 | CHRNB2 (0.50) | BRD4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9965973 | 0.68 | — | — | |
| SCHEMBL34473407 | 0.67 | HPGD (0.50) | SMN1; SMN2 | |
| SCHEMBL16865999 | 0.66 | BRD4 (0.67) | BRD4TP53CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9403806-B1 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9174972-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2015-04-09 | — | — | US | disclosed |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-0630244-B1 | MUSCARINIC AGONISTS | UNIV TOLEDO (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5403845-A | Cognition activators; Alzheimer*s disaease | UNIVERSITY OF TOLEDO (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0630244-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0630244-A4 | MUSCARINIC AGONISTS. | UNIV TOLEDO (US) | 1994-04-07 | — | — | EP | disclosed |
| WO-1993003726-A1 | MUSCARINIC AGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5175166-A | Cognition activators | THE UNIVERSITY OF TOLEDO (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | BRD4 1377/4885TP53 3734/4885CHRNB2 17/4885 |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, CHRM4, CHRM5 | BRD4 1396/4885TP53 2920/4885CHRNB2 18/4885 |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | BRD4 1377/4885TP53 3734/4885CHRNB2 17/4885 |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | BRD4 881/4885TP53 3030/4885CHRNB2 16/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | BRD4 881/4885TP53 3030/4885CHRNB2 16/4885 |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | BRD4 1377/4885TP53 3734/4885CHRNB2 17/4885 |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | BRD4 1377/4885TP53 3734/4885CHRNB2 17/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | BRD4 881/4885TP53 3030/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.